

Product Update:

progesterone 25mg solution for injection (Lubion®)
Pharmasure Ltd

SMC2017

8 June 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

progesterone (Lubion®) is accepted for use within NHS Scotland.

Indication under review: in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.

This increases the range of progesterone preparations available for use in NHS Scotland. Lubion® is an aqueous formulation and may be administered subcutaneously or intramuscularly.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 05 April 2018.

Vice Chairman
Scottish Medicines Consortium